FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164312146> ?p ?o ?g. }

• W2164312146 endingPage "43" @default.
• W2164312146 startingPage "35" @default.
• W2164312146 abstract "Objective To assess the efficacy and safety of tocilizumab (TCZ) plus methotrexate/placebo (MTX/PBO) over 2 years and the course of disease activity in patients who discontinued TCZ due to sustained remission. Methods ACT-RAY was a double-blind 3-year trial. Patients with active rheumatoid arthritis despite MTX were randomised to add TCZ to ongoing MTX (add-on strategy) or switch to TCZ plus PBO (switch strategy). Using a treat-to-target approach, open-label conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), other than MTX, were added from week 24 if Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) >3.2. Between weeks 52 and 104, patients in sustained clinical remission (DAS28-ESR <2.6 at two consecutive visits 12 weeks apart) discontinued TCZ and were assessed every 4 weeks for 1 year. If sustained remission was maintained, added csDMARDs, then MTX/PBO, were discontinued. Results Of the 556 randomised patients, 76% completed year 2. Of patients entering year 2, 50.4% discontinued TCZ after achieving sustained remission and 5.9% achieved drug-free remission. Most patients who discontinued TCZ (84.0%) had a subsequent flare, but responded well to TCZ reintroduction. Despite many patients temporarily stopping TCZ, radiographic progression was minimal, with differences favouring add-on treatment. Rates of serious adverse events and serious infections per 100 patient-years were 12.2 and 4.4 in add-on and 15.0 and 3.7 in switch patients. In patients with normal baseline values, alanine aminotransferase elevations >3×upper limit of normal were more frequent in add-on (14.3%) versus switch patients (5.4%). Conclusions Treat-to-target strategies could be successfully implemented with TCZ to achieve sustained remission, after which TCZ was stopped. Biologic-free remission was maintained for about 3 months, but most patients eventually flared. TCZ restart led to rapid improvement. Trial registration number NCT00810199." @default.
• W2164312146 created "2016-06-24" @default.
• W2164312146 creator A5001936700 @default.
• W2164312146 creator A5004025365 @default.
• W2164312146 creator A5004498996 @default.
• W2164312146 creator A5008067100 @default.
• W2164312146 creator A5032343592 @default.
• W2164312146 creator A5043219883 @default.
• W2164312146 creator A5052842332 @default.
• W2164312146 creator A5075261558 @default.
• W2164312146 creator A5077099389 @default.
• W2164312146 creator A5082221558 @default.
• W2164312146 date "2014-08-28" @default.
• W2164312146 modified "2023-10-01" @default.
• W2164312146 title "Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study" @default.
• W2164312146 cites W1761300068 @default.
• W2164312146 cites W2005429018 @default.
• W2164312146 cites W2010363255 @default.
• W2164312146 cites W2018118744 @default.
• W2164312146 cites W2025591723 @default.
• W2164312146 cites W2075327204 @default.
• W2164312146 cites W2096862304 @default.
• W2164312146 cites W2096965824 @default.
• W2164312146 cites W2097874407 @default.
• W2164312146 cites W2112234440 @default.
• W2164312146 cites W2114909821 @default.
• W2164312146 cites W2131592263 @default.
• W2164312146 cites W2139339400 @default.
• W2164312146 cites W2141323245 @default.
• W2164312146 cites W2151858167 @default.
• W2164312146 cites W2166232525 @default.
• W2164312146 cites W2168751860 @default.
• W2164312146 cites W2169537705 @default.
• W2164312146 cites W4210768724 @default.
• W2164312146 cites W4253469911 @default.
• W2164312146 doi "https://doi.org/10.1136/annrheumdis-2014-205752" @default.
• W2164312146 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4283697" @default.
• W2164312146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25169728" @default.
• W2164312146 hasPublicationYear "2014" @default.
• W2164312146 type Work @default.
• W2164312146 sameAs 2164312146 @default.
• W2164312146 citedByCount "95" @default.
• W2164312146 countsByYear W21643121462013 @default.
• W2164312146 countsByYear W21643121462014 @default.
• W2164312146 countsByYear W21643121462015 @default.
• W2164312146 countsByYear W21643121462016 @default.
• W2164312146 countsByYear W21643121462017 @default.
• W2164312146 countsByYear W21643121462018 @default.
• W2164312146 countsByYear W21643121462019 @default.
• W2164312146 countsByYear W21643121462020 @default.
• W2164312146 countsByYear W21643121462021 @default.
• W2164312146 countsByYear W21643121462022 @default.
• W2164312146 countsByYear W21643121462023 @default.
• W2164312146 crossrefType "journal-article" @default.
• W2164312146 hasAuthorship W2164312146A5001936700 @default.
• W2164312146 hasAuthorship W2164312146A5004025365 @default.
• W2164312146 hasAuthorship W2164312146A5004498996 @default.
• W2164312146 hasAuthorship W2164312146A5008067100 @default.
• W2164312146 hasAuthorship W2164312146A5032343592 @default.
• W2164312146 hasAuthorship W2164312146A5043219883 @default.
• W2164312146 hasAuthorship W2164312146A5052842332 @default.
• W2164312146 hasAuthorship W2164312146A5075261558 @default.
• W2164312146 hasAuthorship W2164312146A5077099389 @default.
• W2164312146 hasAuthorship W2164312146A5082221558 @default.
• W2164312146 hasBestOaLocation W21643121461 @default.
• W2164312146 hasConcept C126322002 @default.
• W2164312146 hasConcept C141071460 @default.
• W2164312146 hasConcept C142724271 @default.
• W2164312146 hasConcept C197934379 @default.
• W2164312146 hasConcept C204787440 @default.
• W2164312146 hasConcept C27081682 @default.
• W2164312146 hasConcept C2777178219 @default.
• W2164312146 hasConcept C2777575956 @default.
• W2164312146 hasConcept C2778143017 @default.
• W2164312146 hasConcept C2778715236 @default.
• W2164312146 hasConcept C2781059491 @default.
• W2164312146 hasConcept C71924100 @default.
• W2164312146 hasConcept C90924648 @default.
• W2164312146 hasConceptScore W2164312146C126322002 @default.
• W2164312146 hasConceptScore W2164312146C141071460 @default.
• W2164312146 hasConceptScore W2164312146C142724271 @default.
• W2164312146 hasConceptScore W2164312146C197934379 @default.
• W2164312146 hasConceptScore W2164312146C204787440 @default.
• W2164312146 hasConceptScore W2164312146C27081682 @default.
• W2164312146 hasConceptScore W2164312146C2777178219 @default.
• W2164312146 hasConceptScore W2164312146C2777575956 @default.
• W2164312146 hasConceptScore W2164312146C2778143017 @default.
• W2164312146 hasConceptScore W2164312146C2778715236 @default.
• W2164312146 hasConceptScore W2164312146C2781059491 @default.
• W2164312146 hasConceptScore W2164312146C71924100 @default.
• W2164312146 hasConceptScore W2164312146C90924648 @default.
• W2164312146 hasIssue "1" @default.
• W2164312146 hasLocation W21643121461 @default.
• W2164312146 hasLocation W21643121462 @default.
• W2164312146 hasLocation W21643121463 @default.
• W2164312146 hasLocation W21643121464 @default.
• W2164312146 hasLocation W21643121465 @default.
• W2164312146 hasLocation W21643121466 @default.

• next